K.11.1Clinical studies excluded

StudyRationale for exclusion
Amark P, Beck O. Effect of phenylpropanolamine on incontinence in children with neurogenic bladders. A double-blind crossover study. Acta Paediatrica. 1992; 81(4):345–350. Ref ID: AMARK1992Drug not in BNF
Bennett JK, Foote J, El-Leithy TR et al. Terazosin for vesicosphincter dyssynergia in spinal cord-injured male patients. Molecular Urology. 2000; 4(4):415–420. Ref ID: BENNETT2000Observational study
Delauche-Cavallier MC, Richard JM, Buzelin M et al. Alpha-blocker therapy with alfuzosin in neurogenic bladder disease. Neurourology & Urodynamics. 1993; 12(4):343–344. Ref ID: DELAUCHECAVALLIER1993Abstract
Delauche-Cavallier MC, Costa P, Robain R et al. Efficacy and tolerability of 3 doses of intravenous alfuzosin in neurogenic bladder disease. Neurourology & Urodynamics. 1993; 12(4):344–345. Ref ID: DELAUCHECAVALLIER1993AAbstract
Hachen HJ. Clinical and urodynamic assessment of alpha-adrenolytic therapy in patients with neurogenic bladder function. Paraplegia. 1980; 18(4):229–240. Ref ID: HACHEN1980Observational study
Husmann DA. Use of sympathetic alpha antagonists in the management of pediatric urologic disorders. [Review] [49 refs]. Current Opinion in Urology. 2006; 16(4):277–282. Ref ID: HUSMANN2006Review
Kakizaki H, Ameda K, Kobayashi S et al. Urodynamic effects of alpha1-blocker tamsulosin on voiding dysfunction in patients with neurogenic bladder. International Journal of Urology. 2003; 10(11):576–581. Ref ID: KAKIZAKI2003Observational study
Sakakibara R, Hattori T, Uchiyama T et al. Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy? A comparison of prazosin and moxisylyte. Journal of the Autonomic Nervous System. 2000; 79(2–3):191–195. Ref ID: SAKAKIBARA2000Wrong drug comparison
Swierzewski SJ, III, Gormley EA, Belville WD et al. The effect of terazosin on bladder function in the spinal cord injured patient. Journal of Urology. 1994; 151(4):951–954. Ref ID: SWIERZEWSKI1994Observational study
Vaidyanathan S.Rao. Possible use of indoramin in patients with chronic neurogenic bladder dysfunction. Journal of Urology 129 (1):96–101, 1983.Observational study
Yamanishi T, Yasuda K, Homma Y et al. A multicenter placebo-controlled, double- blind trial of urapidil, an alpha-blocker, on neurogenic bladder dysfunction. European Urology. 1999; 35(1):45–51. Ref ID: YAMANISHI1999Drug not in BNF
Yasuda K, Yamanishi T, Kawabe K et al. The effect of urapidil on neurogenic bladder: a placebo controlled double-blind study. Journal of Urology. 1996; 156(3):1125–1130. Ref ID: YASUDA1996Drug not in BNF

From: Appendix K, Excluded studies

Cover of Urinary Incontinence in Neurological Disease
Urinary Incontinence in Neurological Disease: Management of Lower Urinary Tract Dysfunction in Neurological Disease.
NICE Clinical Guidelines, No. 148.
National Clinical Guideline Centre (UK).
Copyright © 2012, National Clinical Guideline Centre.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Clinical Guideline Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.